Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence Into Action MOST POPULAR Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 August 20, 2020 ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ February 7, 2019 News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... June 20, 2020 Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Load more HOT NEWS Join the Great American Smokeout for a Healthier Tomorrow Answers to Your Questions About Sunscreen Ingredients Speaking with One Cancer Voice for cancer patients in England Coronavirus reports – Part 10: “I didn’t see my mum before...
